However, our findings, although specific for keratinocytes carrying the mutation KRT14 R125P, highlight the potential for unlocking key aspects of as yet unresolved G–P correlations, with implications for novel therapy development, including modulation of inflammation and infection, improvement of wound healing, skin regeneration, and consequent improvement of wound management and the overall quality of life of patients in both EBS and other EB subtypes. The gene discussed is KRT14; the disease is epidermolysis bullosa.